Collaborations & Alliances

Pfizer, AbCellera in Multi-Target Research Pact

Aims to generate lead antibody candidates using AbCellera’s mAb discovery platform

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbCellera Biologics, Inc. has entered a new therapeutic antibody discovery collaboration with Pfizer to apply its monoclonal antibody (mAb) screening platform to discover function-modulating antibodies against undisclosed membrane protein targets.    AbCellera will receive an upfront payment and research support, and will be eligible to receive as much as $90 million in milestones, and royalties based on Pfizer’s development and commercialization of antibodies generated under this collaboratio...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters